Page 114 - Read Online

Spencer et al. J Cancer Metastasis Treat 2022;8:2 https://dx.doi.org/10.20517/2394-4722.2021.174 Page 13 of 15

70. PubMed PMC
12. Uchibori M, Nishida Y, Nagasaka T, Yamada Y, Nakanishi K, Ishiguro N. Increased expression of membrane-type matrix
metalloproteinase-1 is correlated with poor prognosis in patients with osteosarcoma. Int J Oncol 2006. PubMed
13. Futamura N, Nishida Y, Urakawa H, et al. EMMPRIN co-expressed with matrix metalloproteinases predicts poor prognosis in patients
with osteosarcoma. Tumour Biol 2014;35:5159-65. DOI PubMed
14. Bjørnland K, Flatmark K, Pettersen S, Aaasen AO, Fodstad O, Maelandsmo GM. Matrix metalloproteinases participate in
osteosarcoma invasion. J Surg Res 2005;127:151-6. DOI PubMed
15. Xiao X, Wang W, Zhang H, et al. Individualized chemotherapy for osteosarcoma and identification of gene mutations in osteosarcoma.
Tumour Biol 2015;36:2427-35. DOI PubMed
16. Choy E, Hornicek F, MacConaill L, et al. High-throughput genotyping in osteosarcoma identifies multiple mutations in
phosphoinositide-3-kinase and other oncogenes. Cancer 2012;118:2905-14. DOI PubMed PMC
17. Ho XD, Phung P, Q Le V, et al. Whole transcriptome analysis identifies differentially regulated networks between osteosarcoma and
normal bone samples. Exp Biol Med (Maywood) 2017;242:1802-11. DOI PubMed PMC
18. Engelholm LH, Melander MC, Hald A, et al. Targeting a novel bone degradation pathway in primary bone cancer by inactivation of
the collagen receptor uPARAP/Endo180. J Pathol 2016;238:120-33. DOI PubMed
19. Biswas S, Rankin K, Long A, et al. Abstract 5580: Membrane-Type 1 Matrix Metalloproteinase (MT1-MMP): a predictive biomarker
of chemotherapy response in osteosarcoma. Cancer Res 2012;72:5580. DOI
20. Wen X, Liu H, Yu K, Liu Y. Matrix metalloproteinase 2 expression and survival of patients with osteosarcoma: a meta-analysis.
Tumour Biol 2014;35:845-8. DOI PubMed
21. Li H, Zhang K, Liu LH, et al. A systematic review of matrix metalloproteinase 9 as a biomarker of survival in patients with
osteosarcoma. Tumour Biol 2014;35:5487-91. DOI PubMed
22. Liu Y, Wang Y, Teng Z, et al. Matrix metalloproteinase 9 expression and survival of patients with osteosarcoma: a meta-analysis. Eur
J Cancer Care (Engl) 2017;26:e12364. DOI PubMed
23. Yamamoto Y, Yamamoto N, Tajima K, et al. Characterization of human multicentric osteosarcoma using newly established cells
derived from multicentric osteosarcoma. J Cancer Res Clin Oncol 2011;137:423-33. DOI PubMed
24. Mohseny AB, Machado I, Cai Y, et al. Functional characterization of osteosarcoma cell lines provides representative models to study
the human disease. Lab Invest 2011;91:1195-205. DOI PubMed
25. Lauvrak SU, Munthe E, Kresse SH, et al. Functional characterisation of osteosarcoma cell lines and identification of mRNAs and
miRNAs associated with aggressive cancer phenotypes. Br J Cancer 2013;109:2228-36. DOI PubMed PMC
26. Giambernardi TA, Grant GM, Taylor GP, et al. Overview of matrix metalloproteinase expression in cultured human cells. Matrix Biol
1998;16:483-96. DOI PubMed
27. Matsumoto Y, Tanaka K, Harimaya K, Nakatani F, Matsuda S, Iwamoto Y. Small GTP-binding protein, Rho, both increased and
decreased cellular motility, activation of matrix metalloproteinase 2 and invasion of human osteosarcoma cells. Jpn J Cancer Res
2001;92:429-38. DOI PubMed PMC
28. Petrova V, Annicchiarico-Petruzzelli M, Melino G, Amelio I. The hypoxic tumour microenvironment. Oncogenesis 2018;7:10. DOI
PubMed PMC
29. Chan CD, Haagensen EJ, Tensaout HA, et al. Co-localisation of intra-nuclear membrane type-1 matrix metalloproteinase and hypoxia
inducible factor-2α in osteosarcoma and prostate carcinoma cells. Oncol Lett 2021;21:158. DOI PubMed PMC
30. Ingvarsen SZ, Gårdsvoll H, van Putten S, et al. Tumor cell MT1-MMP is dispensable for osteosarcoma tumor growth, bone
degradation and lung metastasis. Sci Rep 2020;10:19138. DOI PubMed PMC
31. Wang X, Zhao X, Yi Z, et al. WNT5A promotes migration and invasion of human osteosarcoma cells via SRC/ERK/MMP-14
pathway. Cell Biol Int 2018;42:598-607. DOI PubMed
32. Enomoto M, Hayakawa S, Itsukushima S, et al. Autonomous regulation of osteosarcoma cell invasiveness by Wnt5a/Ror2 signaling.
Oncogene 2009;28:3197-208. DOI PubMed
33. Ren D, Minami Y, Nishita M. Critical role of Wnt5a-Ror2 signaling in motility and invasiveness of carcinoma cells following Snail-
mediated epithelial-mesenchymal transition. Genes Cells 2011;16:304-15. DOI PubMed
34. Liu P, Yang J, Pei J, Pei D, Wilson MJ. Regulation of MT1-MMP activity by β-catenin in MDCK non-cancer and HT1080 cancer
cells. J Cell Physiol 2010;225:810-21. DOI PubMed PMC
35. Guo Y, Zi X, Koontz Z, et al. Blocking Wnt/LRP5 signaling by a soluble receptor modulates the epithelial to mesenchymal transition
and suppresses met and metalloproteinases in osteosarcoma Saos-2 cells. J Orthop Res 2007;25:964-71. DOI PubMed
36. Liu B, Li G, Wang X, Liu Y. A furin inhibitor downregulates osteosarcoma cell migration by downregulating the expression levels of
MT1-MMP via the Wnt signaling pathway. Oncol Lett 2014;7:1033-8. DOI PubMed PMC
37. Lin CH, Ji T, Chen C, Hoang BH. Wnt signaling in osteosarcoma. In: Kleinerman MDE, editor. Current advances in osteosarcoma.
Cham: Springer International Publishing; 2014. p. 33-45. DOI
38. Rubin EM, Guo Y, Tu K, Xie J, Zi X, Hoang BH. Wnt inhibitory factor 1 decreases tumorigenesis and metastasis in osteosarcoma.
Mol Cancer Ther 2010;9:731-41. DOI PubMed PMC
39. Tsuge M, Osaki M, Sasaki R, Hirahata M, Okada F. SK-216, a novel inhibitor of plasminogen activator inhibitor-1, suppresses lung
metastasis of human osteosarcoma. Int J Mol Sci 2018;19:736. DOI PubMed PMC
40. Brennecke P, Arlt MJ, Campanile C, et al. CXCR4 antibody treatment suppresses metastatic spread to the lung of intratibial human
osteosarcoma xenografts in mice. Clin Exp Metastasis 2014;31:339-49. DOI PubMed PMC
41. Zhang F, Chen A, Chen J, Yu T, Guo F. SiRNA-mediated silencing of beta-catenin suppresses invasion and chemosensitivity to